Want to see RADX full AI Analyst Report?
Top Page
Radiopharm Theranostics Limited Sponsored ADR
(NASDAQ:RADX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-35.34% Downside)
Action:Reiterated
Date:09/17/26
The score is driven primarily by weak financial performance: widening losses, negative gross profit, and persistent operating cash burn that increases funding/dilution risk. Technicals further weigh on the score as the stock is in a strong downtrend with negative momentum, despite oversold readings. Valuation provides limited support because the negative P/E is a function of losses and no dividend yield is available.
Positive Factors
RAD101 Clinical Validation
The positive Phase 2b results provide meaningful clinical validation for RAD101 and support progression toward a pivotal global Phase 3 trial. Meeting the primary endpoint could improve partnering prospects and establish a clearer path toward a commercially relevant diagnostic product.
Negative Factors
Deepening Losses
Worsening gross profitability and sharply wider operating losses show that costs are currently scaling faster than revenue. This reflects the company’s pre-commercial development stage and may keep earnings-dependent funding unavailable until clinical programs generate meaningful commercial returns.
Read all positive and negative factors
Positive Factors
Negative Factors
RAD101 Clinical Validation
The positive Phase 2b results provide meaningful clinical validation for RAD101 and support progression toward a pivotal global Phase 3 trial. Meeting the primary endpoint could improve partnering prospects and establish a clearer path toward a commercially relevant diagnostic product.
Read all positive factors
Radiopharm Theranostics Limited Sponsored ADR (RADX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.90M
Dividend YieldN/A
Average Volume (3M)62.25K
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth-19.76%
EPS Growth8.58%
CountryUS
Employees14
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1404.00
Shares Outstanding15,702,943
10 Day Avg. Volume58,124
30 Day Avg. Volume62,252
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.90
Price to Sales (P/S)26.42
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.89
Revenue Forecast (FY)$1.77M
Radiopharm Theranostics Limited Sponsored ADR Business Overview & Revenue Model
Company Description
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating ...
How the Company Makes Money
null...
Radiopharm Theranostics Limited Sponsored ADR Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.71M | 3.63M | 299.23K | 292.36K | 8.83K |
| Gross Profit | -2.10M | 39.28K | 299.23K | 292.36K | 8.83K |
| EBITDA | -66.84M | -38.17M | -44.08M | -31.19M | -17.96M |
| Net Income | -53.94M | -38.34M | -47.95M | -34.61M | -30.34M |
Balance Sheet | |||||
| Total Assets | 60.14M | 86.48M | 72.04M | 74.95M | 83.38M |
| Cash, Cash Equivalents and Short-Term Investments | 4.14M | 29.12M | 18.58M | 11.70M | 26.98M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 37.81M | 43.61M | 44.68M | 29.37M | 20.42M |
| Stockholders Equity | 24.69M | 44.79M | 28.12M | 44.38M | 62.96M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -36.65M | -22.98M | -24.73M | -38.25M |
| Operating Cash Flow | -51.63M | -36.65M | -22.98M | -23.20M | -9.92M |
| Investing Cash Flow | -5.30M | 1.77M | -320.00K | -1.53M | -28.37M |
| Financing Cash Flow | 32.65M | 45.43M | 30.20M | 9.22M | 65.11M |
Radiopharm Theranostics Limited Sponsored ADR Technical Analysis
Negative
2.32
Price Trends
2.43
Negative
3.41
Negative
4.15
Negative
Market Momentum
-0.26
Negative
34.62
Neutral
26.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RADX, the sentiment is Negative. The current price of 2.32 is above the 20-day moving average (MA) of 1.80, below the 50-day MA of 2.43, and below the 200-day MA of 4.15, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 34.62 is Neutral, neither overbought nor oversold. The STOCH value of 26.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RADX.
Radiopharm Theranostics Limited Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | $39.66M | -0.48 | 239.78% | ― | -62.78% | -10.46% | |
48 Neutral | $52.83M | -1.06 | -222.42% | ― | ― | ― | |
48 Neutral | $89.13M | -1.09 | -70.14% | ― | ― | 16.04% | |
42 Neutral | $22.90M | -0.38 | -144.24% | ― | -19.76% | 8.58% |
* General Sector Average
RADX
Radiopharm Theranostics Limited Sponsored ADR
1.62
-4.44
-73.27%
SER
Serina Therapeutics
2.00
-3.25
-61.90%
CELU
Celularity
1.35
-0.69
-33.82%
ACRV
Acrivon Therapeutics, Inc.
2.05
0.19
10.22%
TELO
Telomir Pharmaceuticals, Inc.
1.20
-0.19
-13.67%
Radiopharm Theranostics Limited Sponsored ADR Corporate Events
Radiopharm Theranostics to Present Positive RAD101 Phase 2b Brain Metastases Data at SNO 2026
Sep 14, 2026
On September 14, 2026, Radiopharm Theranostics announced that interim data from its U.S. Phase 2b imaging trial of 18F-RAD101 in suspected recurrent brain metastases have been selected for a late-breaking oral presentation at the Society of Neuro-...
Radiopharm Theranostics Posts Deeper FY26 Loss as R&D Spend Jumps and Cash Reserves Fall
Aug 28, 2026
Radiopharm Theranostics Limited has reported a sharply wider loss for the year ended 30 June 2026, as it stepped up investment in clinical development of its radiopharmaceutical pipeline. Revenue from contracts with customers fell 23.8% to $2.77 m...
Radiopharm Theranostics Secures Multimillion-Dollar Financings to Advance Oncology Radiopharmaceutical Pipeline
Jul 28, 2026
On July 28, 2026, Radiopharm Theranostics closed a registered direct offering of 1,281,646 American Depositary Shares at US$3.16 per ADS, raising about US$4.1 million before fees from U.S. accredited institutional investors, alongside a concurrent...
Radiopharm Theranostics Lists 384 Million New Shares on ASX After ADS Placement
Jul 28, 2026
Radiopharm Theranostics Limited has applied to the Australian Securities Exchange for quotation of 384,493,800 new ordinary fully paid shares, with an issue date of July 28, 2026. The shares, priced at AUD 0.015 each, correspond to 1,281,646 Ameri...
Radiopharm Theranostics Launches Multimillion-Dollar U.S. ADS Offering and Australian Equity Raise to Fund Oncology Pipeline
Jul 27, 2026
Radiopharm Theranostics has arranged a US$4.1 million registered direct offering of 1,281,646 American Depositary Shares and a concurrent private placement of matching unregistered warrants to U.S. institutional investors, under a shelf registrati...
Radiopharm Theranostics Secures A$5.9 Million R&D Tax Refund to Fund Oncology Pipeline
Jul 6, 2026
On July 3, 2026, Radiopharm Theranostics announced it had received an A$5.89 million research and development tax refund from the Australian Government’s RD tax incentive program for the 2025 financial year. The refundable tax offset, which ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.